TherapeuticsMD (TXMD)
NASDAQ:TXMD
TXMD Stock Chart & Stats
$1.68
-$0.07(-6.14%)
At close: 4:00 PM EST
$1.68
-$0.07(-6.14%)
Day’s Range― - ―
52-Week Range$0.86 - $2.95
Previous CloseN/A
Volume92.69K
Average Volume (3M)310.58K
Market Cap
$23.96M
Enterprise Value$21.60M
Total Cash (Recent Filing)$7.48M
Total Debt (Recent Filing)$5.12M
Price to Earnings (P/E)―
Beta1.26
Next Earnings
May 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding11,574,362
10 Day Avg. Volume897,126
30 Day Avg. Volume310,579
Financial Highlights & Ratios
PEG Ratio0.45
Price to Book (P/B)0.70
Price to Sales (P/S)6.24
P/FCF Ratio7.68
Enterprise Value/Market Cap0.90
Enterprise Value/Revenue7.15
Enterprise Value/Gross Profit10.21
Enterprise Value/Ebitda-7.15
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.17
Revenue Forecast (FY)$9.30M
Bulls Say, Bears Say
Bulls Say
Improving Cash GenerationTherapeuticsMD returned to positive operating and free cash flow in 2025, producing $2.45M and improving versus 2024. Sustained positive cash generation provides operational runway, funds strategic alternatives, and reduces near-term financing needs if maintained over several quarters.
Stronger Balance Sheet And Lower LeverageDebt reduction and a modest debt-to-equity ratio indicate a cleaner capital structure versus prior years. Lower leverage and positive equity improve financial flexibility for licensing, potential M&A or asset-sale execution and reduce bankruptcy risk over a multi-quarter horizon.
Shift To Asset-light Royalty ModelGrowing license/royalty revenue and an explicit move toward an asset-light royalty model reduce capital intensity and operating leverage going forward. This structural shift can stabilize margins and cash flow if licensing income scales, making the business less reliant on product commercialization.
Bears Say
Severe Revenue CollapseRevenue falling to zero removes scale economics and undermines any core commercial business. Without meaningful recurring product sales, the company must rely on royalties, one-time transactions, or strategic deals to generate revenue, creating persistent execution risk over months.
Ongoing Operating Losses And Negative ReturnsDespite narrowed losses, continued operating deficits and multi-year negative ROE erode capital and limit reinvestment capacity. Persistent unprofitability increases reliance on external financing or asset sales, constraining long-term growth potential and shareholder value creation.
Erratic Cash Flow Quality And Limited CushionPositive OCF in 2025 is encouraging but has been inconsistent historically; covering only ~50% of debt in 2025 leaves limited buffer against shocks. Modest cash generation versus liabilities can strain flexibility if license revenue or deal proceeds do not materialize.
TherapeuticsMD News
TXMD FAQ
What was TherapeuticsMD’s price range in the past 12 months?
TherapeuticsMD lowest stock price was $0.86 and its highest was $2.95 in the past 12 months.
What is TherapeuticsMD’s market cap?
TherapeuticsMD’s market cap is $23.96M.
When is TherapeuticsMD’s upcoming earnings report date?
TherapeuticsMD’s upcoming earnings report date is May 18, 2026 which is in 36 days.
How were TherapeuticsMD’s earnings last quarter?
TherapeuticsMD released its earnings results on Mar 30, 2026. The company reported -$0.054 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.054.
Is TherapeuticsMD overvalued?
According to Wall Street analysts TherapeuticsMD’s price is currently Overvalued.
Does TherapeuticsMD pay dividends?
TherapeuticsMD does not currently pay dividends.
What is TherapeuticsMD’s EPS estimate?
TherapeuticsMD’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does TherapeuticsMD have?
TherapeuticsMD has 11,574,362 shares outstanding.
What happened to TherapeuticsMD’s price movement after its last earnings report?
TherapeuticsMD reported an EPS of -$0.054 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.508%.
Which hedge fund is a major shareholder of TherapeuticsMD?
Currently, no hedge funds are holding shares in TXMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
TherapeuticsMD
TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; TX-007HR and TX-008HR, which are transdermal patch product candidates; and TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
Technical Analysis
Ownership Overview
1.56% Insiders
3.90% Mutual Funds
20.77% Other Institutional Investors
70.71% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---